Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-24T14:25:53.579Z Has data issue: false hasContentIssue false
  • English
  • Français

Commentary: DLB and PDD: the same or different? Is there a debate?

Published online by Cambridge University Press:  28 January 2009

Ian McKeith
Ian McKeith*
Affiliation:
Institute for Ageing and Health, Newcastle University, Wolfson Research Centre, Campus for Ageing and Vitality, Newcastle upon Tyne, NE4 5PL, U.K. Email: i.g.mckeith@ncl.ac.uk
Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
FOR DEBATE: DEMENTIA WITH LEWY BODIES AND PARKINSON'S DISEASE DEMENTIA: ARE THEY THE SAME ENTITY?
Information
International Psychogeriatrics , Volume 21 , Issue 2 , April 2009 , pp. 220 - 224
Copyright
Copyright © International Psychogeriatric Association 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Aarsland, D., Litvan, I., Salmon, D., Galasko, D., Wentzel-Larsen, T. and Larsen, J. P. (2003). Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease. Journal of Neurology Neurosurgery and Psychiatry, 74, 1215–1220.CrossRefGoogle ScholarPubMed
Aarsland, D., Ballard, C. G. and Halliday, G. (2004). Are Parkinson's disease with dementia and dementia with Lewy bodies the same entity? Journal of Geriatric Psychiatry and Neurology, 17, 137–145.CrossRefGoogle ScholarPubMed
Aarsland, D. et al. (2005a). Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. Journal of Clinical Psychiatry, 66, 633–637.Google ScholarPubMed
Aarsland, D., Perry, R., Brown, A., Larsen, J. P. and Ballard, C. (2005b). Neuropathology of dementia in Parkinson's disease: a prospective, community-based study. Annals of Neurology, 58, 773–776.CrossRefGoogle ScholarPubMed
Ames, D., Ballard, C., Cream, J., Shah, A., Suh, G. H. and McKeith, I. (2005). For debate: should novel antipsychotics ever be used to treat the behavioral and psychological symptoms of dementia (BPSD)? International Psychogeriatrics, 17, 3–29.Google Scholar
Ames, D., Petersen, R. C., Knopman, D. S., Visser, P. J., Brodaty, H. and Gauthier, S. (2006). For debate: is Mild Cognitive Impairment a clinically useful concept? International Psychogeriatrics, 18, 393–414.CrossRefGoogle Scholar
Ames, D. et al. (2007). For debate: is the influence of the pharmaceutical industry on prescribing, research and publication in the field of psychogeriatrics excessive? International Psychogeriatrics, 19, 1003–1020.Google ScholarPubMed
Ames, D., Kaduszkiewicz, H., van den Bussche, H., Zimmermann, T., Birks, J. and Ashby, D. (2008). For debate: is the evidence for the efficacy of cholinesterase inhibitors in the symptomatic treatment of Alzheimer's disease convincing or not? International Psychogeriatrics, 20, 259–292.CrossRefGoogle ScholarPubMed
Ballard, C. et al. (2001). The progression of cognitive impairment in dementia with Lewy bodies, vascular dementia and Alzheimer's disease. International Journal of Geriatric Psychiatry, 16, 499–503.CrossRefGoogle ScholarPubMed
Ballard, C. G. et al. (2004). Neuropathological substrates of psychiatric symptoms in prospectively studied patients with autopsy-confirmed dementia with Lewy bodies. American Journal of Psychiatry, 161, 843–849.Google Scholar
Ballard, C. et al. (2006). Differences in neuropathologic characteristics across the Lewy body dementia spectrum. Neurology, 67, 1931–1934.CrossRefGoogle ScholarPubMed
Beyer, M. K., Larsen, J. P. and Aarsland, D. (2007). Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. Neurology, 69, 747–754.Google Scholar
Beyer, K., Domingo-Sabat, M., Humbert, J., Carrato, C., Ferrer, I. and Ariza, A. (2008). Differential expression of alpha-synuclein, parkin, and synphilin-1 isoforms in Lewy body disease. Neurogenetics, 9, 163–72.CrossRefGoogle ScholarPubMed
Bibl, M. et al. (2006). CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain, 129, 1177–1187.Google Scholar
Bogaerts, V. et al. (2007). A novel locus for dementia with Lewy bodies: a clinically and genetically heterogeneous disorder. Brain, 130, 2277–2291.CrossRefGoogle ScholarPubMed
Bonanni, L., Thomas, A., Tiraboschi, P., Perfetti, B., Varanese, S. and Onofrj, M. (2008). EEG comparisons in early Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease with dementia patients with a 2-year follow-up. Brain, 131, 690–705.CrossRefGoogle ScholarPubMed
Braak, H., Del Tredici, K., Rub, U., de Vos, R. A. I., Jansen Steur, E. N. H. and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24, 197–211.Google Scholar
Brønnick, K. S., Nordby, H., Larsen, J. P. and Aarsland, D. (2008). Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: a mismatch negativity study. Neurobiology of Aging. doi: 10.1016/j.neurobiolaging.2008.02.021 (epublished ahead of print).Google Scholar
Burn, D. et al. (2006a). Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement Disorders, 21, 1899–1907.Google Scholar
Burn, D. J., Rowan, E. N., Allan, L. M., Molloy, S., O'Brien, J. T. and McKeith, I. G. (2006b). Motor subtype and cognitive decline in Parkinson's disease, Parkinson's disease with dementia, and dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 77, 585–589.Google Scholar
Burton, E. J., McKeith, I. G., Burn, D. J., Williams, E. D. and O'Brien, J. T. (2004). Cerebral atrophy in Parkinson's disease with and without dementia: a comparison with Alzheimer's disease, dementia with Lewy bodies and controls. Brain, 127, 791–800.CrossRefGoogle ScholarPubMed
Calne, D. B. and Mizuno, Y. (2004). The neuromythology of Parkinson's disease. Parkinsonism and Related Disorders, 10, 319–322.CrossRefGoogle ScholarPubMed
Colloby, S. and O'Brien, J. T. (2004). Functional imaging in Parkinson's disease and dementia with Lewy bodies. Journal of Geriatric Psychiatry and Neurology, 17, 158–163.Google Scholar
Colloby, S. J. et al. (2006). In vivo SPECT imaging of muscarinic acetylcholine receptors using (R,R) 123I-QNB in dementia with Lewy bodies and Parkinson's disease dementia. Neuroimage, 33, 423–429.CrossRefGoogle Scholar
Downes, J. J., Priestley, N. M., Doran, M., Ferran, J., Ghadiali, E. and Cooper, P. (1998). Intellectual, mnemonic, and frontal functions in dementia with Lewy bodies: a comparison with early and advanced Parkinson's disease. Behavioural Neurology, 11, 173–183.Google Scholar
Dubois, R. et al. (2007). Diagnostic procedures for Parkinson's disease dementia: recommendations from the Movement Disorder Society Task Force. Movement Disorders, 22, 2314–2324.Google Scholar
Emre, M. et al. (2007). Clinical diagnostic criteria for dementia associated with Parkinson's disease. Movement Disorders, 22, 1689–1707.CrossRefGoogle ScholarPubMed
Ferman, T. J. et al. (2007). Dementia with Lewy Bodies. Neurologic Clinics, 45, 741–750.Google Scholar
Francis, P. T. and Perry, E. K. (2007). Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Movement Disorders, 22 (Suppl. 17), S351–357.CrossRefGoogle ScholarPubMed
Fujishiro, H. et al. (2008). Validation of the neuropathologic criteria of the Third Consortium for Dementia with Lewy Bodies for prospectively diagnosed cases. Journal of Neuropathology and Experimental Neurology, 67, 649–656.Google Scholar
Ganguli, M., Dombrovski, A. Y., Mulsant, B. H., Wilkinson, P., Tharyan, P. and Flint, A. (2007). For debate: the evidence for electroconvulsive therapy (ECT) in the treatment of severe late-life depression. International Psychogeriatrics, 19, 9–35.CrossRefGoogle Scholar
Giasson, B. I. et al. (2003). Initiation and synergistic fibrillization of tau and alpha-synuclein. Science, 300, 636–640.Google Scholar
Harding, A. J. and Halliday, G. M. (2001). Cortical Lewy body pathology in the diagnosis of dementia. Acta Neuropathologica (Berlin), 102, 355–363.Google Scholar
Harding, A. J., Broe, G. A. and Halliday, G. M. (2002). Visual hallucinations in Lewy body disease related to Lewy bodies in the temporal lobe. Brain, 125, 391–403.Google Scholar
Hurtig, H. I. et al. (2000). Alpha-synuclein cortical Lewy bodies correlate with dementia in Parkinson's disease. Neurology, 54, 1916–1921.Google Scholar
Jellinger, K. A., Seppi, K., Wenning, G. K. and Poewe, W. (2002). Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. Journal of Neural Transmission, 109, 329–39.Google Scholar
Kovari, E. et al. (2003). Lewy body densities in the entorhinal and anterior cingulate cortex predict cognitive deficits in Parkinson's disease. Acta Neuropathologica (Berlin), 106, 83–88.Google Scholar
Kramer, M. L. and Schulz-Schaeffer, W. J. (2007). Presynaptic alpha-synuclein aggregates, not Lewy bodies, cause neurodegeneration in dementia with Lewy bodies. Journal of Neuroscience, 27, 1405–1410.CrossRefGoogle Scholar
Kurz, M. W., Schlitter, A. M., Larsen, J. P., Ballard, C. and Aarsland, D. (2006). Familial occurrence of dementia and parkinsonism: a systematic review. Dementia and Geriatric Cognitive Disorders, 22, 288–295.Google Scholar
Lane, R., He, Y., Morris, C., Leverenz, J. B., Empe, M. and Ballard, C. (2008). BuChE-K and APOE ϵ4 allete frequencies in Lewy body dementias, and influence of genotype and hyperhomocysteinemia on cognitive decline. Movement Disorders, doi: 10.1002/mds.22357, e-published ahead of print.Google Scholar
Lashley, T. et al. (2008). Cortical alpha-synuclein load is associated with amyloid-beta plaque burden in a subset of Parkinson's disease patients. Acta Neuropathologica, 115, 417–425.CrossRefGoogle Scholar
Levy, G. (2007). The relationship of Parkinson disease with aging. Archives Neurology, 64, 1242–1246.Google Scholar
Lippa, C. F. et al. (2007). DLB and PDD boundary issues: diagnosis, treatment, molecular pathology, and biomarkers. Neurology, 68, 812–819.Google Scholar
Macinnes, N. et al. (2008). Proteasomal abnormalities in cortical Lewy body disease and the impact of proteasomal inhibition within cortical and cholinergic systems. Journal of Neural Transmission, 115, 869–878.Google Scholar
Mastaglia, F. L., Johnsen, R. D., Byrnes, M. L. and Kakulas, B. A. (2003). Prevalaence of amyloid-beta deposition in the cerebral cortex in Parkinson's disease. Movement Disorders, 18, 81–86.Google Scholar
McKeel, D. W. et al. (2004). Neuropathologic criteria for diagnosing Alzheimer disease in persons with pure dementia of Alzheimer type. Journal of Neuropathology and Experimental Neurology, 63, 1028–1037.Google Scholar
McKeith, I. G. et al. (1996). Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): Report of the Consortium on DLB International Workshop. Neurology, 47, 1113–1124.Google Scholar
McKeith, I. G. et al. (2005). Diagnosis and management of dementia with Lewy bodies: Third Report of the DLB Consortium. Neurology, 65, 1863–1872.CrossRefGoogle ScholarPubMed
Merdes, A. R. et al. (2003). Influence of Alzheimer pathology on clinical diagnostic accuracy in dementia with Lewy bodies. Neurology, 60, 1586–1590.Google Scholar
Molloy, S. A., Rowan, E. N., O'Brien, J. T., McKeith, I. G., Wesnes, K. and Burn, D. J. (2006). Effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. Journal of Neurology, Neurosurgery and Psychiatry, 77, 1323–1328.Google Scholar
O'Brien, K. K. et al. (2003). Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics, 13, 231–239.Google Scholar
O'Brien, J. T. et al. (2004). Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Archives of Neurology, 61, 919–925.CrossRefGoogle ScholarPubMed
O'Brien, J. T., Wahlund, L.O., Scheltens, P. and Förstl, H. (2007). For debate: should neuroimaging be a routine investigation in all cases of suspected dementia? International Psychogeriatrics, 19, 525–538.Google Scholar
Parnetti, L. et al. (2008). Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biological Psychiatry, 64, 850–855.Google Scholar
Perry, E., McKeith, I. and Ballard, C. (2003). Butyrylcholinesterase and progression of cognitive deficits in dementia with Lewy bodies. Neurology, 60, 1852–1853.Google Scholar
Piggott, M. A. et al. (1998). Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. Biological Psychiatry, 44, 765–774.Google Scholar
Piggott, M. A. et al. (1999). Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. Brain, 122, 1449–1468.Google Scholar
Revuelta, G. J., Rosso, A. and Lippa, C. F. (2008). Neuritic pathology as a correlate for synaptic loss in dementia with Lewy bodies. American Journal of Alzheimer's Disease and Other Dementias, 23, 97–102.Google Scholar
SantaCruz, K. et al. (1999). Lewy body, neurofibrillary tangle and senile plaque pathology in Parkinson's disease patients with and without dementia. Neurology, 52 (Suppl 2), A476.Google Scholar
Selkoe, D. J. (2008). Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behavioural Brain Research, 192, 106–113.Google Scholar
Taki, J., Yoshita, M., Yamada, M. and Tonami, N. (2004). Significance of 123I-MIBG scintigraphy as a pathophysiological indicator in the assessment of Parkinson's disease and related disorders: it can be a specific marker for Lewy body disease. Annals of Nuclear Medicine, 18, 453–461.CrossRefGoogle ScholarPubMed
Tokuda, T. et al. (2006). Decreased alpha-synuclein in cerebrospinal fluid of aged individuals and subjects with Parkinson's disease. Biochemical and Biophysical Research Communications, 349, 162–166.Google Scholar
Weisman, D. et al. (2007). In dementia with Lewy bodies, Braak stage determines phenotype, not Lewy body distribution. Neurology, 69, 356–359.Google Scholar
Whitwell, J. L. et al. (2007). Focal atrophy in dementia with Lewy bodies on MRI: a distinct pattern from Alzheimer's disease. Brain, 130, 708–719.Google Scholar